Synthetic Reader-Actuators Targeted to Polycomb-Silenced Genes Block Triple-Negative Breast Cancer Proliferation and Invasion.
Lauren HongNatecia L WilliamsMaya JaffeCara E ShieldsKarmella A HaynesPublished in: GEN biotechnology (2023)
Scientists have used pharmacological inhibitors of polycomb proteins to restore the expression of tumor suppressor genes and stop cancer proliferation and invasion. A major limitation of this approach is that key transcriptional activators, such as TP53 and BAF SWI/SNF, are often mutated in cancer. Poor clinical results for polycomb-targeting therapies in solid cancers, including triple-negative breast cancer (TNBC), could discourage the further development of epigenetic monotherapies. Here, we performed epigenome actuation with a synthetic reader-actuator (SRA) that binds trimethylated histone H3 lysine 27 in polycomb chromatin and modulates core transcriptional activators. In SRA-expressing TNBC BT-549 cells, 122 genes become upregulated ≥2-fold, including the genes involved in cell death, cell cycle arrest, and migration inhibition. The SRA-expressing spheroids showed reduced size in Matrigel and loss of invasion. Therefore, targeting Mediator-recruiting regulators to silenced chromatin can activate tumor suppressors and stimulate anti-cancer phenotypes, and further development of robust gene regulators might benefit TNBC patients.
Keyphrases
- cell cycle arrest
- cell death
- genome wide
- transcription factor
- genome wide identification
- dna methylation
- gene expression
- papillary thyroid
- pi k akt
- cancer therapy
- squamous cell
- newly diagnosed
- ejection fraction
- end stage renal disease
- bioinformatics analysis
- induced apoptosis
- poor prognosis
- copy number
- dna damage
- lymph node metastasis
- squamous cell carcinoma
- childhood cancer
- signaling pathway
- prognostic factors
- young adults
- binding protein
- long non coding rna
- patient reported